Test Kit Type: HCV Test Kit (Rapid)
Result Time: Within 3 Minutes
Sensitivity: 100% WHO Evaluation
Specificity: 98.9% WHO Evaluation
Intended Use
The 4th Generation HCV TRI-DOT is a rapid, visual, sensitive and qualitative in vitro diagnostic test for the detection of (IgM,IgG & IgA) antibodies to Hepatitis C virus in human serum or plasma.
It has been developed and designed with increased sensitivity for core and NS3 antibodies using a unique combination of modified HCV antigen.
Salient Features
- Based on “Flow Through Technology”, which is similar to Elisa technology because of involvement of washing steps at various levels to enhance the specificity.
- Use of highly purified HCV antigens for Core, NS3, NS4, NS5 immobilized on the device.
- Detection of all the subtypes of HCV.
- Results within 3 minutes.
- In built quality control dot which validates the test.
- 100% Sensitivity & 98.9% Specificity as per WHO evaluation.
- Shelf life : 24 months at 2-8°C
Principle
- HCV antigens are immobilized on a porous immunofiltration membrane. Sample and the reagents pass through the membrane and are absorbed into the underlying absorbent pad.
- As the patient’s sample passes through the membrane, HCV antibodies if present in serum/plasma, bind to the immobilized antigens. In the subsequent washing step, unbound serum/ plasma proteins are removed.
- In the next step, the protein-A conjugate is added which binds to the Fc portion of the HCV antibodies to give distinct pinkish purple dot against a white background at the test region (“T1” &/or “T2”). At the control region (“C”) a “Built-in Quality Control Dot” has been devised to confirm the proper functioning of the device, reagent and correct procedural application.
Ordering Information
Product Name | Pack Size | Catalog No. |
---|---|---|
HCV TRI-DOT | 50 Tests | HC020050 |
100 Tests | HC020100 |
Evaluations
WHO EVALUATION:The kit has been evaluated by WHO Collaborating Centres by using various panels from Latin America ,Asia, Europe &,African origin along with various sero -conversion panels from BBI including World wide performance panel and anti- HCV low titer performance panel. The Evaluation indicated the following results- Sensitivity 100% & Specificity 98.9%.
PATH USA:Evaluated by PATH USA,(199 reference specimens from US, Indonesia & India) indicated Sensitivity of 100 % & Specificity of 99.2 %.
AIIMS NEW DELHI:An evaluation by Department of Microbiology, All India Institute of Medical Sciences (AIIMS) New Delhi, INDIA (A national reference centre of Government of India) has indicated its Sensitivity 100% and Specificity 100%.
CMC VELLORE:An Evaluation by CMC Vellore (on reference panel of 100 Samples indicated Sensitivity 100 % & Specificity 100 %.
Approved by Drug Controller General of India( DCGI) for the usage in Blood Banks.
Reviews
There are no reviews yet.